- Home
- IPSC vs FIGX Comparison
IPSC vs FIGX Comparison
Compare IPSC & FIGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IPSC | FIGX |
|---|---|---|
| Founded | 2019 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.7M | 195.8M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | IPSC | FIGX |
|---|---|---|
| Price | $2.33 | $10.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 26.4K |
| Earning Date | 03-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,337,000.00 | N/A |
| Revenue This Year | $1,590.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4122.69 | N/A |
| 52 Week Low | $0.34 | $9.95 |
| 52 Week High | $2.71 | $10.15 |
Technical Indicators
Market Signals| Indicator | IPSC | FIGX |
|---|---|---|
| Relative Strength Index (RSI) | 65.56 | 61.02 |
| Support Level | $2.08 | $10.10 |
| Resistance Level | $2.71 | $10.12 |
| Average True Range (ATR) | 0.33 | 0.01 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 67.24 | 86.67 |
Price Performance
Historical ComparisonAbout IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About FIGX FIGX Capital Acquisition Corp. Class A Ordinary Share
FIGX Capital Acquisition Corp is a blank check company.